[1] Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis[J]. Lancet, 2017, 389(10080): 1756-1770. [2] Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management[J]. Mayo Clin Proc, 2014, 89(11): 1553-1563. [3] Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies[J]. Clin Gastroenterol Hepatol, 2012, 10(6): 639-645. [4] Cosin-Roger J, Ortiz-Masia D, Calatayud S, et al. M2 macrophages activate WNT signaling pathway in epithelial cells: relevance in ulcerative colitis[J]. PLoS One, 2013, 8(10): e78128. [5] Shenoy AK, Fisher RC, Butterworth EA, et al. Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors[J]. Cancer Res, 2012, 72(19): 5091-5100. [6] Shimodate Y, Takanashi K, Waga E, et al. Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis[J]. Case Rep Gastroenterol, 2011, 5(1): 159-165. [7] Marteau P, Nelet F, Lelu M, et al. Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France[J]. Aliment Pharmacol Ther, 1996, 10(6): 949-956. [8] Fiorentini MT, Fracchia M, Galatola G, et al. Acute pancreatitis during oral 5-aminosalicylic acid therapy[J]. Dig Dis Sci, 1990, 35(9): 1180-1182. [9] Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus[J]. Gastroenterology, 2015, 148(5): 1035-1058. [10]Hoentjen F1, Sakuraba A, Hanauer S. Update on the management of ulcerative colitis[J]. Curr Gastroenterol Rep, 2011, 13(5): 475-485. [11]Ji Q, Liu X, Fu X, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/beta-catenin signal pathway[J]. PLoS One, 2013, 8(11): e78700. [12]Yao J, Wei C, Wang JY, et al. Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice[J]. World J Gastroenterol, 2015, 21(21): 6572-6581. [13]Samsamikor M, Daryani NE, Asl PR, et al. Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study[J]. Arch Med Res, 2016, 47(4): 304-309. [14]Yuan SX, Wang DX, Wu QX, et al. BMP9/p38 MAPK is essential for the antiproliferative effect of resveratrol on human colon cancer[J]. Oncol Rep, 2016, 35(2): 939-947. [15]Li D, Wang G, Jin G, et al. Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway[J]. Int J Mol Med, 2019, 43(1): 630-640. [16]Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia[J]. Cancer Cell, 2010, 17(1): 28-40. [17]Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities[J]. Nat Med, 2008, 14(11): 1271-1277. [18]王 茜, 崔香丽. 白藜芦醇通过下调miR-31-5p的表达抑制细胞增殖[D]. 山西医科大学, 2018: 1~80 [19]宋 娟, 王 佳, 李宝红, 等. PI3K/Akt信号通路在白藜芦醇抗大鼠缺血/再灌注性心律失常中的作用及机制[J]. 中国应用生理学杂志, 2017, 33(3) : 239-243. [20]Samsami-Kor M, Daryani NE, Asl PR, et al. Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: A randomized, double-blind, placebo-controlled pilot study[J]. Arch Med Res, 2015, 46(4): 280-285. [21]Yao J, Wang J Y, Liu L, et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis[J]. Arch Med Res, 2010, 41(4): 288-294. [22]Cui X, Jin Y, Hofseth AB, et al. Resveratrol suppresses colitis and colon cancer associated with colitis[J]. Cancer Prev Res (Phila), 2010, 3(4): 549-559. [23]Abdallah DM, Ismael NR. Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats[J]. Can J Physiol Pharmacol, 2011, 89(11): 811-818. [24]Macdonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases[J]. Dev Cell, 2009, 17(1): 9-26. [25]Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control[J]. Science, 2014, 346(6205): 1248012. [26]Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared[J]. Trends Mol Med, 2002, 8(1): 10-16. [27]Koch S. Extrinsic control of Wnt signaling in the intestine[J]. Differentiation, 2017, 97: 1-8. [28]黄循铷, 王承党, 王瑞幸, 等. 溃疡性结肠炎小鼠肠道通透性改变与TNF-α及NF-κB P65的关系[J]. 中国应用生理学杂志, 2016, 32(2) : 112-115. [29]Goretsky T, Bradford EM, Ryu H, et al. A cytosolic multiprotein complex containing p85alpha is required for beta-catenin activation in colitis and colitis-associated cancer[J]. J Biol Chem, 2016, 291(8): 4166-4177. [30]Cosin-Roger J, Ortiz-Masia D, Calatayud S, et al. The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD[J]. Mucosal Immunol, 2016, 9(4): 986-998. [31]Clevers H, Nusse R. Wnt/beta-catenin signaling and disease[J]. Cell, 2012, 149(6): 1192-1205. [32]Wang CJ, Stratmann J, Zhou ZG, et al. Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells[J]. BMC Cancer, 2010, 10: 616. [33]Chen T, Yao L Q, Shi Q, et al. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1alpha (FIH-1)[J]. Cancer Biol Ther, 2014, 15(5): 516-523. |